Karpanen Terhi, Wirzenius Maria, Mäkinen Taija, Veikkola Tanja, Haisma Hidde J, Achen Marc G, Stacker Steven A, Pytowski Bronislaw, Ylä-Herttuala Seppo, Alitalo Kari
Molecular/Cancer Biology Laboratory, Biomedicum Helsinki, P.O.B. 63 (Haartmaninkatu 8), FI-00014 University of Helsinki, Finland.
Am J Pathol. 2006 Aug;169(2):708-18. doi: 10.2353/ajpath.2006.051200.
Lymphatic vessel plasticity and stability are of considerable importance when attempting to treat diseases associated with the lymphatic vasculature. Development of lymphatic vessels during embryogenesis is dependent on vascular endothelial growth factor (VEGF)-C but not VEGF-D. Using a recombinant adenovirus encoding a soluble form of their receptor VEGFR-3 (AdVEGFR-3-Ig), we studied lymphatic vessel dependency on VEGF-C and VEGF-D induced VEGFR-3 signaling in postnatal and adult mice. Transduction with AdVEGFR-3-Ig led to regression of lymphatic capillaries and medium-sized lymphatic vessels in mice under 2 weeks of age without affecting collecting lymphatic vessels or the blood vasculature. No effect was observed after this period. The lymphatic capillaries of neonatal mice also regressed partially in response to recombinant VEGFR-3-Ig or blocking antibodies against VEGFR-3, but not to adenovirus-encoded VEGFR-2-Ig. Despite sustained inhibitory VEGFR-3-Ig levels, lymphatic vessel regrowth was observed at 4 weeks of age. Interestingly, whereas transgenic expression of VEGF-C in the skin induced lymphatic hyperplasia even during embryogenesis, similar expression of VEGF-D resulted in lymphangiogenesis predominantly after birth. These results indicate considerable plasticity of lymphatic vessels during the early postnatal period but not thereafter, suggesting that anti-lymphangiogenic therapy can be safely applied in adults.
在尝试治疗与淋巴管系统相关的疾病时,淋巴管的可塑性和稳定性至关重要。胚胎发育过程中淋巴管的形成依赖于血管内皮生长因子(VEGF)-C而非VEGF-D。我们使用编码其受体VEGFR-3可溶性形式的重组腺病毒(AdVEGFR-3-Ig),研究了出生后及成年小鼠淋巴管对VEGF-C和VEGF-D诱导的VEGFR-3信号传导的依赖性。用AdVEGFR-3-Ig进行转导导致2周龄以下小鼠的毛细淋巴管和中等大小淋巴管消退,而不影响集合淋巴管或血管系统。在此之后未观察到效果。新生小鼠的毛细淋巴管也会因重组VEGFR-3-Ig或抗VEGFR-3阻断抗体而部分消退,但对腺病毒编码的VEGFR-2-Ig无反应。尽管VEGFR-3-Ig水平持续受到抑制,但在4周龄时仍观察到淋巴管再生。有趣的是,虽然皮肤中VEGF-C的转基因表达即使在胚胎期也会诱导淋巴管增生,但VEGF-D的类似表达主要在出生后导致淋巴管生成。这些结果表明,出生后早期淋巴管具有相当大的可塑性,而此后则不然,这表明抗淋巴管生成疗法可安全应用于成年人。